-DNA It's a misconception that high economic growth translates into employment A recent report prepared by the consultancy firm PricewaterhouseCoopers for the Confederation of Indian Industry (CII) harps on the usual premise of boosting economic growth as the basis for job creation. Accordingly, it will still take 20 years to remove unemployment even if India grows at an annual growth rate of 9 per cent. This is exactly what we were...

-The Hindu Only un-electrified households will be entitled to subsidised fuel New Delhi: Attacking the subsidy regime, Union Finance Minister Arun Jaitley has scrapped the supply of subsidised kerosene through the Public Distribution System (PDS). The Centre plans to write to States asking them to provide subsidised kerosene only to un-electrified households. States which have achieved near 100 per cent electrification will be incentivised to become kerosene-free, a Finance Ministry source told...

-Down to Earth National Human Rights Commission has sought report from the state The K Chandrasekhar Rao government in Telangana seems to have failed to deliver on its promise of reforming the crisis-ridden farm sector in the state. Unofficial figures suggest that more than 400 farmers have committed suicide in the past six months. Telangana, the youngest state in the country, came into existence on June 2 this year. Rao and other leaders...

-PTI NEW DELHI: India has showed some improvement in addressing corruption this year, ranking 85th among 175 countries as against 94th last year, graft watchdog Transparency International India (TII) said on Wednesday. Denmark retained its position as the least corrupt country in 2014 with a score of 92 while North Korea and Somalia shared the last place, scoring just 8, it said. In India's neighbourhood, China moved to 100th place, down from 80th...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...